List of Excipients in API deucravacitinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing deucravacitinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| ER Squibb & Sons LLC | SOTYKTU | deucravacitinib | 0003-0895 | ANHYDROUS LACTOSE | 2027-09-09 |
| ER Squibb & Sons LLC | SOTYKTU | deucravacitinib | 0003-0895 | CELLULOSE, MICROCRYSTALLINE | 2027-09-09 |
| ER Squibb & Sons LLC | SOTYKTU | deucravacitinib | 0003-0895 | CROSCARMELLOSE SODIUM | 2027-09-09 |
| ER Squibb & Sons LLC | SOTYKTU | deucravacitinib | 0003-0895 | FERRIC OXIDE RED | 2027-09-09 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for deucravacitinib
Excipient focus: ANHYDROUS LACTOSE
deucravacitinib drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
deucravacitinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
deucravacitinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
deucravacitinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
deucravacitinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 06081224
deucravacitinib drug variants containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
deucravacitinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
deucravacitinib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
deucravacitinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
deucravacitinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
deucravacitinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
deucravacitinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ER Squibb & Sons LLC | deucravacitinib | 0003-0895 |
| >Company | >Ingredient | >NDC |
deucravacitinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch